It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
originally posted by: Thoughtful3
a reply to: Thoughtful3
I'm totally creeped out.
#2222
No.
Highest classification.
Consider the vastness of space.
8 words. #2222=8 and this is from 8 chan. N=13, C= 3= 16. H=8...16-8=8.
in reality, Covid has led to a precious type of immunization for some:
that against manipulation.
Those who have not understood what happened have not developed antibodies and are still manipulated by media propaganda on any topic.
originally posted by: Thoughtful3
I could go on and on...
These maneuvers will last 12 days, and will take place in northern Norway, Sweden and Finland, not far from the Russian border, and will involve 20,000 soldiers from 14 countries including Italy, America, France, Great Britain, the Netherlands and the United States.
20,000 NATO soldiers are also participating in exercises in Poland, to demonstrate that NATO is ready and able to protect its people and defend every part of its allies' territory.
Methemoglobinemia, or methaemoglobinaemia, is a condition of elevated methemoglobin in the blood. Symptoms may include headache, dizziness, shortness of breath, nausea, poor muscle coordination, and blue-colored skin (cyanosis). Complications may include seizures and heart arrhythmias.
Methemoglobinemia can be due to certain medications, chemicals, or food or it can be inherited. Substances involved may include benzocaine, nitrites, or dapsone. The underlying mechanism involves some of the iron in hemoglobin being converted from the ferrous [Fe2+] to the ferric [Fe3+] form. The diagnosis is often suspected based on symptoms and a low blood oxygen that does not improve with oxygen therapy. Diagnosis is confirmed by a blood gas.
Treatment is generally with oxygen therapy and methylene blue. Other treatments may include vitamin C, exchange transfusion, and hyperbaric oxygen therapy. Outcomes are generally good with treatment. Methemoglobinemia is relatively uncommon, with most cases being acquired rather than genetic.
Methylthioninium chloride, commonly called methylene blue, is a salt used as a dye and as a medication. As a medication, it is mainly used to treat methemoglobinemia by chemically reducing the ferric iron in hemoglobin to ferrous iron. Specifically, it is used to treat methemoglobin levels that are greater than 30% or in which there are symptoms despite oxygen therapy. It has previously been used for treating cyanide poisoning and urinary tract infections, but this use is no longer recommended.
Methylene blue is typically given by injection into a vein. Common side effects include headache and vomiting. While use during pregnancy may harm the baby, not using it in methemoglobinemia is likely more dangerous.
Methylene blue was first prepared in 1876, by Heinrich Caro. It is on the World Health Organization's List of Essential Medicines.
Methylene blue (MB), as the first fully man-made medicine, has a wide range of clinical applications. Apart from its well-known applications in surgical staining, malaria, and methemoglobinemia, the anti-oxidative properties of MB recently brought new attention to this century-old drug. Mitochondrial dysfunction has been observed in systematic aging that affects many different tissues, including the brain and skin. This leads to increaseding oxidative stress and results in downstream phenotypes under age-related conditions. MB can bypass Complex I/III activity in mitochondria and diminish oxidative stress to some degree. This review summarizes the recent studies on the applications of MB in treating age-related conditions, including neurodegeneration, memory loss, skin aging, and a premature aging disease, progeria.